Lentigo Maligna Clinical Trial
Official title:
A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails
The purpose of this study is to investigate the effectiveness of using either radiotherapy (RT) or Imiquimod (ImiQ) to treat the Lentigo Maligna (LM), when surgery is not possible, is refused, or fails.
Surgery is the standard treatment for people diagnosed with LM. However for some people, it may not be possible due to the location of their LM lesion(s). Currently, the Australian and New Zealand Melanoma Treatment Guidelines recommend radiotherapy for the treatment of LM however there is no clinical trial evidence for this and a trial is needed to prove which treatment is safer and more effective. Some clinicians may also recommend the use of a cream called Imiquimod. It is approved and widely used in Australia to treat solar keratosis, superficial basal cell carcinoma, external genital warts, and perianal warts. Although not currently licensed for treatment use in LM, there is some evidence to suggest that it is both safe and effective in treating LM. This trial will scientifically evaluate and compare these two treatments in a controlled clinical setting. The primary objective of this trial is to compare the rate of LM treatment failure and recurrence rate measured at 24 months (primary endpoint), and measured at 6, 12 months (secondary endpoints) following treatment with ImiQ or RT. For this study, treatment failure includes both the recurrence and persistence of LM, and is defined as the presence of LM cells within the original field of treatment confirmed by histopathology. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06046144 -
Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
|
||
| Completed |
NCT00707174 -
Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna
|
N/A | |
| Completed |
NCT03508297 -
Reflectance Confocal Microscopy to Diagnose MM & LM
|
||
| Withdrawn |
NCT02306512 -
Mohs and Immunofluorescence for Malignant Melanoma In Situ
|
N/A | |
| Completed |
NCT01161888 -
Effect of Topical Imiquimod on Lentigo Maligna
|
Phase 4 | |
| Completed |
NCT02723721 -
Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face
|
Phase 2 | |
| Terminated |
NCT04688749 -
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
|
||
| Active, not recruiting |
NCT01088737 -
Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna
|
Phase 2/Phase 3 | |
| Completed |
NCT02685592 -
Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream
|
Phase 4 | |
| Completed |
NCT00785369 -
In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis
|
N/A | |
| Recruiting |
NCT06014619 -
Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
|